tiprankstipranks
Trending News
More News >
Lenz Therapeutics, Inc. (LENZ)
:LENZ
US Market

LENZ Therapeutics (LENZ) Earnings Dates, Call Summary & Reports

Compare
172 Followers

Earnings Data

Report Date
Aug 13, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
-0.62
Last Year’s EPS
-0.4
Same Quarter Last Year
Based on 8 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:May 07, 2025
|
% Change Since: 7.89%
|
Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Positive
The earnings call presents a strong and positive outlook for LENZ Therapeutics, with significant progress in financial strength, pre-launch activities, and commercial readiness. Despite potential regulatory and economic challenges, the company appears well-prepared for the upcoming launch of LNZ100.
Company Guidance
During the LENZ Therapeutics First Quarter 2025 Financial Results Conference Call, the management shared several key metrics and strategic updates. The company is preparing for the potential launch of LNZ100, with a PDUFA target action date set for August 8, 2025. LENZ has a strong financial footing with approximately $194.1 million in cash, cash equivalents, and marketable securities as of the end of Q1 2025, and expects to have over $185 million at PDUFA. The commercial strategy is structured around three pillars: enabling doctors to recommend LNZ100, empowering patients to request it by name, and ensuring a seamless path to access. The unbranded EYEAMSELECTIVE campaign has generated over 2 million online impressions and engaged more than 12,000 eye care professionals (ECPs). The sales force build-out is on track, with over 40% of offers accepted for the 88 sales territories. The company aims to have the full sales team in place by July 1, 2025. LENZ's Phase III CLARITY study showed that 90% of participants noticed an improvement in near vision, and 75% indicated they would continue using LNZ100 post-study. The company is targeting a $3 billion-plus market opportunity with an estimated 128 million Americans affected by presbyopia.
Strong Financial Position
LENZ Therapeutics ended Q1 2025 with approximately $194.1 million in cash, cash equivalents, and marketable securities. They received net proceeds of $16.3 million from a block trade, further strengthening their financial position.
High Engagement in Pre-Launch Campaigns
The unbranded EYEAMSELECTIVE campaign generated strong engagement with over 2 million impressions and reached over 12,000 eye care professionals (ECPs).
Positive Feedback from Commercial Day
The Commercial Day at the NASDAQ market site received extremely positive feedback, with many investors and analysts attending. The event demonstrated the strength of LENZ’s commercial strategy.
Sales Force and Commercial Readiness
LENZ has hired over 40% of its sales force, with 97% having prior eye care or pharma experience. The goal is to have the full field team in place by July 1st.
Strong Clinical Data
Phase III CLARITY study showed 90% of participants noticed an improvement in near vision, and 75% indicated they would continue using LNZ100.
---

LENZ Therapeutics (LENZ) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

LENZ Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 13, 2025
2025 (Q2)
-0.61 / -
-0.4
May 07, 2025
2025 (Q1)
-0.52 / -0.53
-3.5384.99% (+3.00)
Mar 19, 2025
2024 (Q4)
-0.41 / -0.46
-2.57582.14% (+2.12)
Nov 06, 2024
2024 (Q3)
-0.46 / -0.38
-2.74986.18% (+2.37)
Aug 14, 2024
2024 (Q2)
-0.48 / -0.40
-6.7994.11% (+6.39)
May 08, 2024
2024 (Q1)
-0.82 / -3.53
-3.01-17.28% (-0.52)
Mar 18, 2024
2023 (Q4)
-0.91 / -2.77
-3.0810.19% (+0.31)
Nov 08, 2023
2023 (Q3)
-0.25 / -0.24
-0.4546.67% (+0.21)
Sep 11, 2023
2023 (Q2)
-0.97 / -0.97
-0.48-102.08% (-0.49)
May 11, 2023
2023 (Q1)
-0.33 / -0.43
-0.4810.42% (+0.05)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

LENZ Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 07, 2025
$25.34$25.87+2.09%
Mar 19, 2025
$25.52$26.30+3.06%
Nov 06, 2024
$28.65$32.23+12.50%
Aug 14, 2024
$23.50$22.60-3.83%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Lenz Therapeutics, Inc. (LENZ) report earnings?
Lenz Therapeutics, Inc. (LENZ) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
    What is Lenz Therapeutics, Inc. (LENZ) earnings time?
    Lenz Therapeutics, Inc. (LENZ) earnings time is at Aug 13, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is LENZ EPS forecast?
          LENZ EPS forecast for the fiscal quarter 2025 (Q2) is -0.62.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis